Article

Anti-obesity drug inhibits prostate Ca in animal model

The anti-obesity drug orlistat (Xenical) has been found to inhibit prostate cancer growth in a study of mice.

Newsletter

Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

Subscribe Now!
Related Videos
Sarah Razavi, MD, answers a question during a Zoom video interview
Sarah Razavi, MD, outlines strategies for mitigate surgeon discomfort during URS
Human urinary bladder | Image Credit: © magicmine - stock.adobe.com
Can ctDNA detect molecular residual disease in NMIBC?
Kevin T. McVary, MD, FACS, answers a question during a Zoom video interview
Expert discusses setting realistic expectations for Rezum for BPH
1 expert is featured in this series.
Considering Therapy De-Intensification: Balancing Adverse Effects and PSA Response
Nicolette G. Payne, MD, answers a question during a Zoom video interview
Nicolette G. Payne, MD, discusses risk factors for burnout among pediatric urologists
Andrea Pezzella, MD, URPS, FACOG, answers a question during a Zoom video interview
Sacral neuromodulation device empowers patients with greater UUI control
Howard Goldman, MD, on his experience with the Glean Urodynamics System
Howard Goldman, MD, on his experience with the Glean Urodynamics System
Remaining Unmet Needs in NMIBC: Closing Thoughts From Expert Panel
Remaining Unmet Needs in NMIBC: Closing Thoughts From Expert Panel
Urology Crossroads: Looking Ahead in the Era of Immunotherapy for NMIBC
Urology Crossroads: Looking Ahead in the Era of Immunotherapy for NMIBC
Blur image of hospital corridor | Image Credit: © zephyr_p - stock.adobe.com
Study: Women with SCI are more likely to use indwelling catheters
Related Content
Water vapor therapy demonstrates superior outcomes vs pharmaceutical therapy for BPH
July 22nd 2025

Water vapor therapy demonstrates superior outcomes vs pharmaceutical therapy for BPH

Hannah Clarke
According to the authors, these data support Rezūm as an alternative first-line treatment option for patients at risk of BPH progression.
Pearls & Perspectives: Testosterone and the Future of Men’s Health, with John P. Mulhall, MD
July 15th 2025

Pearls & Perspectives: Testosterone and the Future of Men’s Health, with John P. Mulhall, MD

Amy M. Pearlman, MD
Mulhall offers an unfiltered, evidence-based deep dive into testosterone evaluation and treatment nuances.
Mitomycin intravesical solution demonstrates long-term durability in LG-IR-NMIBC
July 21st 2025

Mitomycin intravesical solution demonstrates long-term durability in LG-IR-NMIBC

Hannah Clarke
Mitomycin intravesical solution was granted FDA approval in June 2025 for recurrent LG-IR-NMIBC.
Pearls & Perspectives: Disruptive Innovation in Urology, with Sijo J. Parekattil, MD
June 30th 2025

Pearls & Perspectives: Disruptive Innovation in Urology, with Sijo J. Parekattil, MD

Amy M. Pearlman, MD
Pearlman and Parekattil dig deep into novel surgical and non-surgical approaches to chronic orchialgia and pelvic pain.
Prostate cancer cells dividing | Image Credit: © PRB ARTS - stock.adobe.com
July 18th 2025

Phase 3 TALAPRO-2 data of talazoparib plus enzalutamide published in The Lancet

Hannah Clarke
In both cohorts, the combination of talazoparib plus enzalutamide led to a significant improvement in overall survival vs enzalutamide alone.
Urology in focus: Key moments from 2025
July 18th 2025

Urology in focus: Key moments from 2025

Hannah Clarke
Take a look back through some of the top stories from the first half of the year.
© 2025 MJH Life Sciences

All rights reserved.